Cargando…

CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia

INTRODUCTION: Cognitive enhancers (ie, cholinesterase inhibitors and memantine) can provide symptomatic benefit for some individuals with dementia; however, there are circumstances in which the risks of continuing treatment may potentially outweigh benefits. The decision to deprescribe cognitive enh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrmann, Nathan, Ismail, Zahinoor, Collins, Rhonda, Desmarais, Philippe, Goodarzi, Zahra, Henri‐Bhargava, Alexandre, Iaboni, Andrea, Kirkham, Julia, Massoud, Fadi, Moser, Andrea, Silvius, James, Watt, Jennifer, Seitz, Dallas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Special Topic Section
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802736/ https://www.ncbi.nlm.nih.gov/pubmed/35128025 http://dx.doi.org/10.1002/trc2.12099

Ejemplares similares

CCCDTD5: research diagnostic criteria for Alzheimer's Disease
por: Gauthier, Serge, et al.
Publicado: (2020)

CCCDTD5 recommendations on early and timely assessment of neurocognitive disorders using cognitive, behavioral, and functional scales
por: Tang‐Wai, David F., et al.
Publicado: (2020)

CCCDTD5 recommendations on early non cognitive markers of dementia: A Canadian consensus
por: Montero‐Odasso, Manuel, et al.
Publicado: (2020)

Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment
por: Smith, Eric E., et al.
Publicado: (2020)

CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment
por: Brisson, Mélanie, et al.
Publicado: (2021)

CCCDTD5: Reducing the risk of later‐life dementia. Evidence informing the Fifth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD‐5)
por: Rockwood, Kenneth, et al.
Publicado: (2020)

Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4)
por: Gauthier, Serge, et al.
Publicado: (2012)

Evaluation of physicians’ knowledge of deprescribing, deprescribing tools and assessment of factors affecting deprescribing process
por: Akande-Sholabi, Wuraola, et al.
Publicado: (2023)

Policies for Deprescribing: An International Scan of Intended and Unintended Outcomes of Limiting Sedative-Hypnotic Use in Community-Dwelling Older Adults
por: Shaw, James, et al.
Publicado: (2019)

CCCDTD5: Individual and community‐based psychosocial and other non‐pharmacological interventions to support persons living with dementia and their caregivers
por: Vedel, Isabelle, et al.
Publicado: (2020)

Facilitators and Barriers Influencing Antipsychotic Medication Prescribing and Deprescribing Practices in Critically Ill Adult Patients: a Qualitative Study
por: Jaworska, Natalia, et al.
Publicado: (2023)

Antihypertensive Deprescribing in Older Adults: a Practical Guide
por: Sheppard, James P., et al.
Publicado: (2022)

A National Modified Delphi Consensus Process to Prioritize Experiences and Interventions for Antipsychotic Medication Deprescribing Among Adult Patients With Critical Illness
por: Jaworska, Natalia, et al.
Publicado: (2022)

Deprescribing: Practical Ways to Support Person-Centred, Evidence-Based Deprescribing
por: Le Bosquet, Katherine, et al.
Publicado: (2019)

Person‐centered assessment of people living with dementia: Review of existing measures
por: Mast, Benjamin T., et al.
Publicado: (2021)

Person‐centered assessment of apathy and resistance to care in people living with dementia: Review of existing measures
por: Mast, Benjamin T., et al.
Publicado: (2022)

Evaluation of environmental assessment tools for settings for individuals living with dementia
por: Calkins, Margaret P., et al.
Publicado: (2022)

Understanding Global Deprescribing Policy: Opportunities and Challenges
por: Kim, Catherine, et al.
Publicado: (2021)

Deprescribing in older people
por: Liacos, Michelle, et al.
Publicado: (2020)

DEPRESCRIBING IN ASSISTED LIVING
por: Zarowitz, Barbara, et al.
Publicado: (2022)

Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing
por: Farrell, Barbara, et al.
Publicado: (2016)

Fast zwei Jahre Coronapandemie aus der Perspektive von Krebsbetroffenen
por: Gaisser, Andrea, et al.
Publicado: (2022)

Correction: Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis
por: Delara, Mahin, et al.
Publicado: (2022)

Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis
por: Delara, Mahin, et al.
Publicado: (2022)

Attitudes of ambulatory care older Nepalese patients towards deprescribing and predictors of their willingness to deprescribe
por: Shrestha, Shakti, et al.
Publicado: (2021)

Enhancing deprescribing: A qualitative understanding of the complexities of pharmacist‐led deprescribing in care homes
por: Birt, Linda, et al.
Publicado: (2022)

Deprescribing in Palliative Cancer Care
por: Hedman, Christel, et al.
Publicado: (2022)

Symposium Abstract Deprescribing in Psychiatry
por: Mudgal, Varchasvi, et al.
Publicado: (2022)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

Deprescribing: What is the gold standard? Themes that characterized the discussions at the first Danish symposium on evidence-based deprescribing
por: Kaas Oldenburg, Lykke I., et al.
Publicado: (2022)

Polypharmacy and Medication-Related Problems in Hemodialysis Patients: A Call for Deprescribing
por: Alshamrani, Majed, et al.
Publicado: (2018)

Gynecomastia Management: An Evolution and Refinement in Technique at UT Southwestern Medical Center
por: Bailey, Steven H., et al.
Publicado: (2016)

Remote training and evaluation of a simulator-based training course for complex endovascular procedures
por: Plimon, Markus, et al.
Publicado: (2023)

Deprescribing—A Few Steps Further
por: Sadowski, Cheryl A.
Publicado: (2018)

Deprescribing: Fashion Accessory or Fig Leaf?
por: Zermansky, Arnold G.
Publicado: (2019)

Antipsychotics for elderly with psychosis: Deprescribe or continue?
por: Mohr, P.
Publicado: (2021)

Intestinal microbiome-gut-brain axis and irritable bowel syndrome
por: Moser, Gabriele, et al.
Publicado: (2017)

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
por: Moser, Tobias, et al.
Publicado: (2022)

En bloc resection of bladder tumour: the rebirth of past through reminiscence
por: Teoh, Jeremy Yuen-Chun, et al.
Publicado: (2023)

Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review
por: Pollmann, André S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1tjum5g7n3u1bv0luh3gk1j894